AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06305754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 5 mg/mL\*min via IV infusion
Study NCT06305754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 Receptor Antagonist
Description: Administered as rescue medication per approved product label
Study NCT06305754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H2 Receptor Antagonist
Description: Administered as rescue medication per approved product label
Study NCT06305754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (or equivalent)
Description: Administered as rescue medication per approved product label
Study NCT06305754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (or equivalent)
Description: Administered as rescue medication per approved product label
Study NCT06305754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Mouthwash (dexamethasone or equivalent)
Description: Administered as rescue medication per approved product label
Study NCT05643846 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QLB procedure after cesarean section
Description: Bupivacaine local anesthetic drug used for QLB procedure after Cesarean section. Intervention of two different concentration of Bupivacaine, 0.125% or 0.25%, at a dose of 0.2 ml/kg.
Study NCT06399419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06399419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06399419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CBM588 Capsules
Description: Given PO
Study NCT06399419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06399419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT06399419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06399419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04813822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miconazole Nitrate 2% + Domiphen Bromide Low Dose
Description: Dosage 1
Study NCT04813822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miconazole Nitrate 2% + Domiphen Bromide High Dose
Description: Dosage 2
Study NCT04813822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miconazole Nitrate 2%
Description: Active Comparator
Study NCT06528262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enavogliflozin
Description: Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days
Study NCT06528262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days
Study NCT05009628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: automated oxygenation with a sitting patient position in the ICU
Description: Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2> 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
Study NCT05009628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated oxygenation with the patient lying down in the ICU
Description: Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2> 94%. The patient's position in the ICU will be a recumbent position with the head elevated to a maximum of 10
Study NCT05009628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygenation is controlled with the patient in a sitting position in the ICU.
Description: ICU. Oxygenation will be done via the same interface in manual mode where the post-interventional monitoring room nurse modifies the flow to maintain oxygen saturation above 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
Study NCT06144814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid vaginal gel
Description: . Group II received 5 mg of vaginal hyaluronic acid every day for 14 days, then 2 days a week for the next 2 weeks. Hyaluronic acid gel for vaginal use was supplied by ORTHOGEN®. The treatment period lasted 1 month in both groups.
Study NCT06144814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen vaginal use form
Description: Group I received 25 µg vaginal estrodiol (Vagifem®). 1 tablet a day for two weeks, then 2 times a week for the next 2 weeks.
Study NCT06386575 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group; Patients who received physiological saline
Description: All patients will be given 1 gram of paracetamol intravenously + 20 milligrams of tenoxicam + 8 milligrams of decort intravenously. Paracetamol 3x1 gram + tenoxicam 2x20 milligrams will continue to be administered. Patients in the control group will be given 40 milliliters of physiological saline during the suprainguinal fascia iliaca block.
Study NCT06386575 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: suprainguinal fascia block; Patients receiving local anesthetic
Description: All patients will be given 1 gram of paracetamol intravenously + 20 milligrams of tenoxicam + 8 milligrams of decort intravenously. Paracetamol 3x1 gram + tenoxicam 2x20 milligrams will continue to be administered. Patients in the sfıb group will be given 40 milliliters of 0.25 % bupivacaine during the suprainguinal fascia iliaca block.
Study NCT04818047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VID-KIDS Intervention Program
Description: Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Videofeedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol.
Study NCT06192693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution
Description: 1 FMT=30 capsulized FMT given during 2 days in several intakes per day (3 intakes per day).~FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion >8%.
Study NCT06192693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsulized placebo transfer containing dilution solution
Description: 1 Placebo of FMT=30 capsulized given during 2 days in several intakes per day (3 intakes per day).~Placebo of FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion >8%.
Study NCT05711017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huashibaidu granule
Description: Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the Huashibaidu group will receive Huashibaidu granule two times a day for five consecutive days (day 1\~5).
Study NCT05711017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the placebo group will receive placebo two times a day for five consecutive days (day 1\~5).
Study NCT04542109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: READyR A
Description: Two active sessions to conduct an individually-tailored dementia-related needs assessment, incorporating the participant's care values and objective data from remote in-home monitoring.
Study NCT04542109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: READyR B
Description: Active comparator. Two sessions to deliver general information about dementia-related care needs.
Study NCT05300217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategies for promoting mental health
Description: Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding strategies for promoting mental health
Study NCT04985292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic, Lactobacillus
Description: 10\^10 colony-forming units of a Lactobacillus strain, packaged in a capsule, once daily
Study NCT04985292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance packaged to be identical to active treatment
Study NCT04917003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RIC plus EDAS
Description: Patients who are allocated into RIC group will undergo EDAS surgery combined 3-month RIC treatment. The opposite operation will be performed at 3 months after the first operation.
Study NCT04917003 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EDAS
Description: Patients who are allocated into the control group will accept EDAS surgery twice. The second operation will be performed at 3 months after the first operation.
Study NCT05136885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS-005
Description: Administration: Infusion Dose: 0.75 g/kg weekly
Study NCT05136885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Administration: Infusion Dose: equivalent weight-based volume as described for trehalose
Study NCT06219356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-002
Description: Administered orally according to the assigned treatment schedule.
Study NCT05300217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General information about depression
Description: Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding general information about depression
Study NCT06045364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously
Study NCT06045364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anisodamine
Description: During induction of anesthesia,10mg of Anisodamine was given intramuscular injection.
Study NCT04878562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-COPE
Description: The patient survey will be sent out via MyChart 3 days before the visit. It asks about current pain, goals, treatment history, treatment preferences, and health status. Alternatively, patients will be asked to compete a survey in clinic on paper or a tablet. The surveys will be identical, except screening for screening for depression and opioid use will depend on the availability of previous scores. Survey and the EHR will help auto-generate best practice advisories (BPAs) and a tailored smart set. The smartset is based on AGS and CDC guidelines for chronic pain and opioids. It shows which treatment options are not recommended based on the patient's history, comorbidities, and preferences. The smartset also includes links to decision aid and patient education tools. Personalized action plan will be created with pain rating and goal, treatment plan, and relevant tips and educational materials. Action plan will be clearly laid out using max 6 grade reading level, and simple graphics.
Study NCT06043674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: 2:1 T-cell bispecific humanized monoclonal antibody, 2.5 mL or 10 mL single-use vial, via intravenous infusion per protocol.
Study NCT06043674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glofitamab
Description: 2:1 T-cell bispecific humanized monoclonal antibody, 2.5 mL or 10 mL single-use vial, via intravenous infusion per protocol.
Study NCT06043674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Humanized glycoengineered type II anti-CD20 monoclonal antibody, 50 mL single-use vial, via intravenous infusion per protocol.
Study NCT06043674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Humanized glycoengineered type II anti-CD20 monoclonal antibody, 50 mL single-use vial, via intravenous infusion per protocol.
Study NCT06043674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Antibody-drug conjugate, 30 mg or 140 mg vial, via intravenous infusion per protocol.
Study NCT06043674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Humanized immunoglobulin monoclonal antibody, 840 mg/14 mL or 1200 mg/20 mL single-use vial, via intravenous infusion per protocol.
Study NCT06043674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: For the treatment of Cytokine Release Syndrome. Recombinant, humanized, anti-human monoclonal antibody, 20 mg/mL single-dose vials, via intravenous infusion per protocol.
Study NCT06043674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: For the treatment of Cytokine Release Syndrome. Recombinant, humanized, anti-human monoclonal antibody, 20 mg/mL single-dose vials, via intravenous infusion per protocol.
Study NCT05163366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GROUP A
Description: Rectal Ketamine will be administered at 6 mg/kg and with a rectal nozzle it's infused through the rectum. The rectal ketamine will be administered after scoring pain just before the start of the procedure and then about 15 minutes later the procedure will start when the patient has achieved a nystagmus.
Study NCT05163366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP B
Description: The tradition standard protocols involve the use of 0.3mg/kg of oral morphine about an hour before the start of the procedure before the start of the procedure to allow for the onset of action of oral morphine for every single procedure in this arm.
Study NCT06578923 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard of care
Description: 12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
Study NCT06578923 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient satisfaction questionnare
Description: VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
Study NCT06180824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelafundin
Description: Insulin will be diluted with gelafundin colloid fluid in 50mls syringe and tubing (same product manufacturer).~Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment.
Study NCT06301529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Invokana Pill
Description: 100 mg and 150 mg doses, taken every day and every-other day, respectively.
Study NCT06059261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab and recombinant human endostatin combined with chemoradiotherapy
Description: Induction treatment phase: Envafolimab administered by subcutaneous injection on day 1 every 3 weeks at 300 mg for 3 cycles, cisplatin administered by intravenous infusion on day 1 of each cycle at 80 mg/m2 every 3 weeks for 3 cycles, gemcitabine was administered by intravenous infusion on days 1 and 8 of each cycle at 1 g/m2 every 3 weeks for 3 cycles, recombinant human endostatin was administered on day 1 every 3 weeks at 210 mg for 3 cycles. Concurrent treatment phase: Cisplatin was administered by intravenous infusion on day 1 of each cycle at 100mg/m2 every 3 weeks for 2 cycles. Adjuvant treatment Phase: Envafolimab was administered on day 1 every 3 weeks at 300 mg for 8 cycles as a subcutaneous injection. Intensity-modulated radiotherapy: 69.96Gy/33fractions/7 weeks,5 fractions/week, 1 fraction/day.
Study NCT05917184 — intervention group
Intervention type: OTHER
Intervention: Telehealth
Description: Two video telehealth visits will be conducted and recorded within 3 days of one another (+/- 1 day)
Study NCT06242548 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physical activity outings in the mountains at a level already practised by the subjects, while maintaining their usual diet (normoglucidic or ketogenic)
Description: organisation of 4 physical activity outings in the mountains at a level already practised by the subjects, while maintaining their usual diet (normoglucidic or ketogenic).~During each of of the 4 physical activity outings, collection of capillary blood samples (blood sugar, ketone levels), non-invasive biometric data (weight, oxygen saturation by transcutaneous sensor), and questionnaires (BORG scale, food consumption before/during/after exercise).
Study NCT06521697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia using dexmedetomidine-ketamine-lidocaine mixture
Description: Multimodal analgesia using dexmedetomidine-ketamine-lidocaine mixture vs placebo normal saline
Study NCT06521697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimal flow sevoflurane
Description: Minimal flow sevoflurane anesthesia (0.5 L/min) vs low flow sevoflurane (1 L/min)
Study NCT06301529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Invokana Pill
Description: 100 mg and 150 mg doses, taken every day and every-other day, respectively.
Study NCT05269719 — intervention group
Intervention type: PROCEDURE
Intervention: Suture of digital nerve
Description: The digital nerves were sutured according to the discretion of the treating surgeon and the standard procedure was three epineural sutures 8.0 or 9.0 nylon under loop magnification. Concomitant tendon injuries were also sutured according to the discretion of the treating surgeon, most commonly with two loop sutures (four strand core) and a peritendinous PDS suture.
Study NCT05399082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoprobe biopsy
Description: A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
Study NCT04936100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of distance and near visual acuity using Vision Screening module of Easy Vision application
Description: The presenting visual acuity will be assessed using the Vision Screening module of the Easy Vision application.
Study NCT04936100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of distance and near visual acuity using Test Yourself module of Easy Vision application
Description: The presenting visual acuity will be assessed using the Test Yourself module of the Easy Vision application.
Study NCT04936100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of distance and near visual acuity using Peek Acuity application
Description: The presenting visual acuity will be assessed using the Peek Acuity application.
Study NCT04936100 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of distance and near visual acuity using the conventional methods
Description: The presenting visual acuity will be assessed using the conventional methods \[Chart: Tumbling E optotype for assessing distance visual acuity and Handheld chart: Tumbling E Near Point Vision Chart for assessing near visual acuity\]
Study NCT05609760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIMAP
Description: Pictographic depiction of medical indications alongside standard communication of these recommendations.
Study NCT05609760 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: Standard communication by medical staff of treatment indications for asthma. An informative leaflet will be delivered as well.